(Reuters) -The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio’s therapy for patients with a type of lung cancer.
The once-daily oral drug, with brand name Ibtrozi, is approved to treat ROS1-positive non-small cell lung cancer (NSCLC).
NSCLC affects more than one million people globally, with about 2% having ROS1-positive disease, according to the company.
The drug, taletrectinib, belongs to a class of drugs known as ROS1 inhibitors.
(Reporting by Siddhi Mahatole and Sneha S K in Bengaluru; Editing by Shinjini Ganguli and Vijay Kishore)
